Evidence map›Paper›PMID 40655531›Full record

ArticleJCO oncology advances2025

Phase I Trial to Evaluate the Safety of Intralesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma.

Chia-Ching J Wang, Alexander Bang, Sona Chowdhury, Kieron S Leslie, Ursula E Lang, Michiko Shimoda, Timothy J Henrich, Rebecca Hoh, Steve G Deeks, Chao Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO oncology advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Chia-Ching J WangUniversity of California San Francisco, San Francisco, CA.ORCID https://orcid.org/0009-0000-9753-3345
Alexander BangUniversity of California Los Angeles, Los Angeles, CA.
Sona ChowdhuryUniversity of California San Francisco, San Francisco, CA.
Kieron S LeslieUniversity of California San Francisco, San Francisco, CA.
Ursula E LangUniversity of California San Francisco, San Francisco, CA.
Michiko ShimodaUniversity of California San Francisco, San Francisco, CA.ORCID https://orcid.org/0000-0002-6627-4624
Timothy J HenrichUniversity of California San Francisco, San Francisco, CA.
Rebecca HohUniversity of California San Francisco, San Francisco, CA.ORCID https://orcid.org/0000-0001-5112-4220
Steve G DeeksUniversity of California San Francisco, San Francisco, CA.ORCID https://orcid.org/0000-0001-6371-747X
Chao WangUniversity of California San Francisco, San Francisco, CA.ORCID https://orcid.org/0009-0002-9304-1217
Amelia N DeitchmanUniversity of California San Francisco, San Francisco, CA.
Paul CoueyUniversity of California San Francisco, San Francisco, CA.
Toby MaurerIndiana University, Indianapolis, IN.

Funding

Targeting Non Viral Markers of HIV PersistenceR01AI141003 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HENRICH, TIMOTHY JENSEN · 2018 to 2022
$4.9M
Mentoring Scientists for Careers in HIV Translational Clinical ResearchK24AI174971 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Timothy Jensen Henrich · 2023 to 2026
$766k
NIAID NIH HHS K24 AI174971NIAID NIH HHS R01 AI141003
6 · The paper itself

Abstract

purposeIntralesional vinblastine can induce regression of Kaposi sarcoma (KS), but it is often painful. We conducted a phase I trial to evaluate the safety and tolerability of intralesional injections of nivolumab to treat cutaneous KS. PATIENTS AND

methodsWe enrolled participants with limited cutaneous KS and injected 1 mL (10 mg) of nivolumab into target KS lesions once every 2 weeks for four doses, with optional extension to total of eight doses. Skin biopsy of a target KS lesion was performed at screening and at week 26. The primary end point was safety; the secondary end point was KS response by AIDS Clinical Trials Group criteria.

resultsBetween May 2018 and December 2020, 12 cis-gender men (six living with HIV and six without HIV) were enrolled. Baseline median CD4

conclusionIntralesional nivolumab was safe and well-tolerated in this population of men with limited cutaneous KS.

Identifiers

PMID40655531
PMCPMC12244976

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.